Navigation Links
Next-generation Targeted Cytokine Therapy to be Explored on Advancements Series

An upcoming episode of Advancements with Ted Danson, scheduled to broadcast 2Q/2020, will explore innovative treatment solutions for maladies, such as Inflammatory Bowel Disease (IBD), specifically Crohn’s Disease (Crohn’s), and Oncology. Check local listings for more info.

This segment will focus on a novel platform developed by Deka Biosciences, Inc. (Deka Biosciences), that will enable the delivery of next generation cytokine or combination of cytokines to a specific tissue of interest. Viewers will learn how this cutting-edge technology, termed Diakines™, has led to the development of two potential therapeutic molecules involving an affinity modified Interleukin 10 cytokine.

The show will also explore how Deka Biosciences is using Diakines™ to harness the spectrum of therapeutically useful and clinically validated IL10 and other cytokine specific biologies. Spectators will see how these Diakines™ can maximize patient benefits through improved PK/PD function combined with a MOA directed patient selection strategy.

“The biopharma industry has known for a while that cytokines play an integral role in immunology and disease management, and that delivery of cytokine therapeutics into diseased tissues will dramatically enhance therapeutic benefit,” said Dr. John Mumm, co-founder & CEO of Deka Biosciences. He continued to say, “Deka Biosciences has harnessed the wealth of clinical knowledge around cytokines and IL-10 in particular, to develop a novel delivery platform to enrich cytokine variants in effected tissues, coupled with methods to determine how to select the patients with the greatest likelihood of response to ensure that the right patients get the right medicines.”

In addition, the show will also inform about Deka Biosciences’ Precision Medicine strategy, which enables Deka to identify the right patients to treat with these new medicines.

“Deka’s platform has the potential to enable discoveries of next generation therapies,” said Richard Lubin, senior producer for DMG Productions and the Advancements series. “We are eager to explore how Deka is set to influence future treatment options for IBD, Crohn’s.”

About Deka Biosciences:
Deka BioSciences, Inc., is an early-stage biotech focused on creating the next generation targeted cytokine therapies to treat chronic illnesses such as Crohn’s Disease and Oncology. Deka’s focus is on the development of optimized disease specific IL-10 variants coupled with the DiakinesTM T1/2 life extension tissue targeting technology. In parallel, Deka has developed a Precision Medicine strategy by identifying the genetic signature that drives responses to treatment to enable the selection of the patients most likely to benefit from our therapies.

About Advancements and DMG Productions:
The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming on which both viewers and networks depend.

For more information, please visit or call Richard Lubin at 866-496-4065.

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Octapharma Adopts Genedata Bioprocess to Develop Next-generation Bio-manufacturing Processes
2. Next-Generation VYPR 2 Horticulture Solution Ensures High-Yield, Consistent Harvests in Every Season
3. Next-Generation Biologics: R&D, Industry and Market Forecasts 2015-2025
4. PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis
5. Researcher using next-generation sequencing to rapidly identify pathogens
6. Scientists successfully generate human platelets using next-generation bioreactor
7. Lawrence Livermore Lab awarded $5.6 million to develop next-generation neural devices
8. Next-generation glaucoma therapeutics hold considerable promise
9. CHOP introduces HLA typing by next-generation sequencing to its clinical services
10. Sanford-Burnham receives US Air Force grant to perform next-generation toxicity screens
11. Allen Institute for Brain Science partners with imec for development of next-generation tools
Post Your Comments:
(Date:3/5/2020)... ... March 05, 2020 , ... Diagenode, a leading global ... (MGI), a subsidiary of global genomics leader BGI Group, today announced a co-marketing ... Europe and Asia Pacific. , Under the terms of the non-exclusive agreement, ...
(Date:3/4/2020)... ... 04, 2020 , ... RoosterBio Inc., a leading supplier of ... today a significant milestone in the regenerative medicine field with the dosing of ... treated by RoosterBio’s pharmaceutical customer with an Investigational New Drug (IND) that was ...
(Date:3/2/2020)... (PRWEB) , ... March 02, 2020 , ... Nominations are ... program co-founded by the Security Industry Association (SIA) and SecureIDNews ... SIA Women in Security Forum . The recipients of this year’s Women in Biometrics ...
Breaking Biology News(10 mins):
(Date:2/21/2020)... ... February 21, 2020 , ... Pharmaceutical ... operations in order to adapt to new approaches like ‘Industry 4.0’ and continuous ... demand for personalized medicine and therapies. But with an industry with the world’s ...
(Date:2/19/2020)... ... February 19, 2020 , ... Red Nucleus, a leading provider ... announced the opening of a new office in Tokyo, Japan. The new office ... Nucleus announced the new office in response to customer requests for regional coverage. ...
(Date:2/11/2020)... BALTIMORE (PRWEB) , ... February 11, 2020 , ... ... biosolids and residuals solutions services in North America, today announced that the City ... long-term solution to its biosolids management needs. Commencing in April of 2020, Synagro ...
(Date:2/5/2020)... ... 05, 2020 , ... Rare Disease Day® , held the last day ... Rare Disorders (NORD), to raise awareness amongst the general public and decision-makers about rare ... “Behind The Mystery” rare disease series will be shining the light on ...
Breaking Biology Technology: